Literature DB >> 6519128

Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers.

E Perucca, A Albrici, G Gatti, R Spalluto, M Visconti, A Crema.   

Abstract

The kinetics of oxiracetam after single intravenous and oral doses (2000 mg) were investigated in four healthy volunteers. Following intravenous administration, the decline in serum levels showed a prolonged, rapid phase followed by a delayed terminal phase. Mean residence times ranged from 3.9 to 6.5 h. Volumes of distribution ranged from 0.9 to 1.81 X kg-1, whereas clearance values ranged from 100 to 119 ml X h-1 X kg-1 More than 90% of the intravenous dose was recovered unchanged in the urine within 48 h. Oral administration resulted in peak levels within 1-2 h; thereafter, the decline in serum levels showed a pattern similar to that observed after the intravenous dose--almost 50% of the oral dose was excreted in the urine within 6 h. The absolute availability of oral oxiracetam was 75 +/- 7%.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6519128     DOI: 10.1007/BF03189650

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  4 in total

1.  Disposition of pulse dose methylprednisolone in adult and paediatric patients with the nephrotic syndrome.

Authors:  B M Assael; G Banfi; A C Appiani; A Edefonti; W J Jusko
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

2.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

3.  Determination of common parameters fo iodothyronine metabolism and distribution in man by noncompartmental analysis.

Authors:  J H Oppenheimer; H L Schwartz; M I Surks
Journal:  J Clin Endocrinol Metab       Date:  1975-08       Impact factor: 5.958

4.  Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients.

Authors:  E Perucca; A Richens
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

  4 in total
  10 in total

1.  Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with non-geriatric healthy subjects.

Authors:  J B Lecaillon; J P Dubois; H Coppens; T Darragon; W Theobald; G Reumond; H Beck
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

2.  Pilot study to determine the interaction of oxiracetam with antiepileptic drugs.

Authors:  A van Wieringen; J W Meijer; W van Emde Boas; T A Vermeij
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

3.  Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects.

Authors:  R Grimaldi; E Perucca; G Ruberto; C Gelmi; F Trimarchi; M Hollmann; A Crema
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Comparative kinetics of oxiracetam in serum and CSF of patients with dementia of Alzheimer type.

Authors:  L Parnetti; P Mecocci; A Gaiti; D Cadini; F Lombardi; M Visconti; U Senin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

5.  Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose.

Authors:  J B Lecaillon; J P Dubois; H Coppens; T Darragon; G Reumond; N Pozet; J Traeger; G Lambrey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

6.  Oxiracetam and D-pyroglutamic acid antagonize a disruption of passive avoidance behaviour induced by the N-methyl-D-aspartate receptor antagonist 2-amino-5-phosphonovalerate.

Authors:  F Paoli; G Spignoli; G Pepeu
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 7.  Clinical pharmacokinetics of drugs for Alzheimer's disease.

Authors:  L Parnetti
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

8.  Absorption and disposition of 14C-labelled oxiracetam in rat, dog and man.

Authors:  H P Gschwind; H Schütz; N Wigger; P Bentley
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

9.  Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly.

Authors:  E Perucca; J Parini; A Albrici; M Visconti; E Ferrero
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Apr-Jun       Impact factor: 2.441

Review 10.  Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.

Authors:  Andrei G Malykh; M Reza Sadaie
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.